Drugs / RPTR-1-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07293754 | Dec 2025 → Dec 2028 expected | cancer | Repertoire Immune Medicines | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPTR-1-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07293754 ↗ |
| Modality | Other / unclassified | “RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors” NCT07293754 ↗ |